Bluebird Bio Inc. (NASDAQ:BLUE) gapped up prior to trading on Thursday . The stock had previously closed at $47.46, but opened at $48.09. Bluebird Bio shares last traded at $49.30, with a volume of 668,449 shares.

BLUE has been the subject of several recent research reports. BTIG Research reissued a “buy” rating and issued a $72.00 price objective on shares of Bluebird Bio in a report on Wednesday, April 20th. Leerink Swann reissued a “buy” rating on shares of Bluebird Bio in a report on Monday, June 13th. Goldman Sachs Group Inc. reissued a “neutral” rating and issued a $149.00 price objective on shares of Bluebird Bio in a report on Saturday, April 23rd. Vetr raised Bluebird Bio from a “buy” rating to a “strong-buy” rating and set a $61.43 price objective for the company in a report on Thursday, April 7th. Finally, Janney Montgomery Scott reissued a “buy” rating and issued a $91.00 price objective on shares of Bluebird Bio in a report on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $96.09.

The firm has a 50 day moving average price of $44.29 and a 200-day moving average price of $45.69. The stock’s market capitalization is $1.81 billion.

Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by $0.29. The company earned $1.50 million during the quarter, compared to the consensus estimate of $4.50 million. During the same period in the previous year, the business posted ($0.76) EPS. The business’s revenue was down 76.2% compared to the same quarter last year. Analysts expect that Bluebird Bio Inc. will post ($5.90) earnings per share for the current fiscal year.

In related news, insider Philip D. Gregory sold 2,931 shares of the company’s stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $39.52, for a total transaction of $115,833.12. Following the completion of the sale, the insider now owns 30,069 shares in the company, valued at $1,188,326.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Davidson sold 1,000 shares of the company’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $45.08, for a total value of $45,080.00. Following the sale, the insider now owns 10,600 shares of the company’s stock, valued at approximately $477,848. The disclosure for this sale can be found here.

Other hedge funds have recently bought and sold shares of the company. ProShare Advisors LLC boosted its stake in Bluebird Bio by 6.5% in the fourth quarter. ProShare Advisors LLC now owns 30,869 shares of the company’s stock worth $1,982,000 after buying an additional 1,888 shares during the period. Rhumbline Advisers boosted its stake in shares of Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock worth $2,303,000 after buying an additional 2,023 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Bluebird Bio by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 37,859 shares of the company’s stock worth $2,431,000 after buying an additional 2,385 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Bluebird Bio by 40.8% in the fourth quarter. Nationwide Fund Advisors now owns 40,800 shares of the company’s stock worth $2,620,000 after buying an additional 11,830 shares during the last quarter. Finally, GAM Holding AG bought a new stake in shares of Bluebird Bio during the fourth quarter worth approximately $2,717,000.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.